FDA Authorizes New JUUL2 E-Cigarette System

FDA issued marketing granted orders on 28 August 2026 for Juul Labs' JUUL2 e-cigarette system — the company's first new device hardware in roughly a decade — authorizing both a tobacco-flavored and a menthol-flavored pod. The order is a case study in how FDA's tobacco program applies its central legal test, whether a product is "appropriate for the protection of the public health," to a flavor category the agency has historically treated with the most skepticism.

What FDA authorized

The order covers three products: the JUUL2 device itself, a tobacco-flavored pod at 18 mg/mL nicotine, and a menthol-flavored pod at the same strength — both pods substantially lower in nicotine concentration than the 3% and 5% strengths FDA authorized for the original JUUL device. A Marketing Granted Order permits a company to legally sell a tobacco product in the United States; it is the affirmative outcome of the PMTA review process, the opposite of a Marketing Denial Order, which bars sale outright. FDA's own 2022 denial of the original JUUL product — later reversed in July 2025 — is the clearest illustration of how the same review process can land on either outcome for the same manufacturer.

The population-health standard, applied to menthol

Every PMTA marketing order rests on the same statutory question: is the product, examined against public health as a whole, appropriate to authorize? For a nicotine-delivery product that question has two sides in tension — how many adult smokers switch away from more dangerous combustible cigarettes, against how many non-smokers, particularly youth, the product might newly attract or addict. Flavored products, and menthol specifically, have consistently drawn the most scrutiny under that test, because flavor is one of the strongest documented predictors of youth appeal. Coverage of the JUUL2 order describes FDA citing company-submitted six-week switching data in which adult smokers using the menthol pod had a higher rate of completely switching from cigarettes than those on the tobacco-flavored pod — and concluding that the adult-switching benefit outweighed the youth-uptake risk for this specific product, at this specific nicotine strength, with this specific hardware.

What changed on the device itself

JUUL2 ships with an optional age-verification feature: an accompanying app that must confirm a user's age before the device will unlock and operate. The feature is opt-in rather than mandatory on every unit sold, which means its practical effect on youth access depends on adoption — a detail regulatory and public-health observers are likely to watch as closely as the authorization itself. It is the device's headline design change from the original JUUL hardware, which had no comparable age-gating mechanism built in.

A pattern PMTA sponsors are watching

FDA's tobacco center has authorized a small fraction of the tobacco product applications filed since the PMTA pathway opened — the large majority, including most flavored e-cigarette submissions, have been denied. The JUUL2 order, following the original device's July 2025 authorization, signals that a sponsor with a large adult-switching data set and a credible youth-mitigation feature can clear the bar for a flavored product, not just a tobacco-flavored one. For any regulated-product manufacturer building a submission around a population-health benefit-risk argument — a task drug and device sponsors also face when FDA is asked to weigh a new technology's risk profile against its benefit — the order is a fresh data point on how FDA is currently drawing that line for a well-studied product category.